MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2016 International Congress

June 19-23, 2016. Berlin, Germany.

View by Title View Sessions
View by Date

Tuesday, June 21, 2016

12:30pm-2:00pm
A descriptive study on the safety and feasibility of mesenchymal stem cell therapy for Parkinson’s disease: A case series

M.J.O.V. Buensalido, J.J.A. Tiongson (Pasig City, Philippines)

Therapy in movement disorders: Gene and cell-based therapies  ·  Exhibit Hall located in Hall B, Level 2
12:30pm-2:00pm
A heterozygous splicing variant in NPC2 in a patient with PSP

C. Castro-Fernández, C. García-Sancho, V. Rodríguez-Sureda, R. Martínez-Regueiro, P. Aguiar, P. Blanco-Arias, C. Pérez-Sousa, P. Díaz, C. Domínguez, M. Fernández-Prieto, T. García-Sobrino, J. Cortés, M. Arias, M.J. Sobrido (Santiago de Compostela, Spain)

Rare genetic and metabolic diseases  ·  Exhibit Hall located in Hall B, Level 2
12:30pm-2:00pm
A homozygous loss-of-function mutation in DNAJA3 causes hereditary motor and sensory neuropathy with spastic paraplegia (HMSN type V)

T. Kawarai, R. Miyamoto, Y. Kuroda, M. Omoto, M. Ueyama, N. Murakami, T. Furukawa, R. Oki, A. Mori, Y. Osaki, C. Banzrai, H. Nodera, A. Orlacchio, A. Hashiguchi, Y. Higuchi, H. Takashima, T. Kanda, Y. Izumi, Y. Nagai, T. Mitsui, R. Kaji (Tokushima, Japan)

Spasticity  ·  Exhibit Hall located in Hall B, Level 2
12:30pm-2:00pm
A novel C. elegans model for identification of small molecules that target alpha-synuclein-mediated toxicity

L.V. Kalia, K. Menezes, Y. Zhang, S. Ishikura, N. Tran, H. Chau, A.M. Lozano, S.K. Kalia, J.G. Culotti, S. Suo, W.S. Ryu (Toronto, ON, Canada)

Parkinson's disease: Pathophysiology  ·  Exhibit Hall located in Hall B, Level 2
12:30pm-2:00pm
A novel haplotype in LRRK2 is associated with risk for multiple system atrophy in the Korean population

L.L. Farrell, E. Scott, H.J. Kim, I. Guella, S. Bortnick, E.M. Nosova, B. Jeon, C.W. Sin, H. Park, S.S. Park, M.J. Farrer (Vancouver, Cameroon)

Parkinson's disease: Genetics  ·  Exhibit Hall located in Hall B, Level 2
12:30pm-2:00pm
A novel homozygous DJ1 mutation causes parkinsonism and ALS in a Turkish family

H.A. Hanagasi, A. Giri, G. Guven, B. Bilgic, A.K. Hauser, M. Emre, P. Heutink, N. Basak, T. Gasser, J. Simón-Sánchez, E. Lohmann (Istanbul, Turkey)

Parkinson's disease: Genetics  ·  Exhibit Hall located in Hall B, Level 2
12:30pm-2:00pm
A novel phenotype associated with GRN mutations: Spastic ataxia

I. Faber, J.R.M. Prota, A.R.M. Martinez, B.S. Carvalho, Í.T. Lopes-Cendes, M.C. França Jr (Campinas, Brazil)

Genetics (NON-PD)  ·  Exhibit Hall located in Hall B, Level 2
12:30pm-2:00pm
A novel single molecule imaging approach to detect individual protein oligomers in CSF from patients with Parkinson’s disease (PD)

S. Gandhi, M.H. Horrocks, S.F. Lee, N.W. Wood, D. Klenerman (London, United Kingdom)

Parkinson's disease: Pathophysiology  ·  Exhibit Hall located in Hall B, Level 2
12:30pm-2:00pm
A peripheral pathway to restless legs syndrome? Clues from familial amyloid polyneuropathy

T. Teodoro, P. Viana, D. Abreu, I. Conceição, R. Peralta, J.J. Ferreira (Lisboa, Portugal)

Restless legs syndrome and other sleep disorders  ·  Exhibit Hall located in Hall B, Level 2
12:30pm-2:00pm
A phase 3, placebo-controlled study with an open-label extension: Sustained incobotulinumtoxinA efficacy in upper-limb post-stroke spasticity over 48 weeks

P. Kanovský, A. Brashear, E.P. Elovic, M.C. Munin, A. Hanschmann, R. Hiersemenzel, C. Marciniak (Olomouc, Czech Republic)

Spasticity  ·  Exhibit Hall located in Hall B, Level 2
  • «Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 48
  • Next Page»

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley